Sotatercept drug may foster lung health in severe pulmonary hypertension patients, controlling pathological spread and ...
ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX ...
Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), ...
T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New ...
In a study now published in Nature Plants, Dr. Yihong Feng (Specially Appointed Assistant Professor) and Professor Takashi ...
A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel, Switzerland, have demonstrated ...
About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two ...
The stock options have a ten-year term, and the exercise price is $30.40 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback